Brief: Marvel Biosciences Selects Novotech As Cro For Its Phase I Clinical Trial Of Mb-204
25/03/2026 11:53
Marvel Biosciences Corp MRVL.V: MARVEL BIOSCIENCES SELECTS NOVOTECH AS CRO FOR ITS PHASE I CLINICAL TRIAL OF MB-204 Source text: ID:nGNX8rLJyC Further company coverage: MRVL.V